Genpharmasec531592Quarterly results
Q2 results, Clinigenome stake sale and company secretary resignation approved by the board
Board meeting on 03 November 2026 approved three items.
By ScoutQuest · · 2 min read
| Line item | Latest | Year ago | YoY | Prev qtr | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 8,565.82 | 3,263.71 | +162% | 4,971.03 | +72.3% |
| Total income | 8,671.85 | 3,310.19 | +162% | 5,008.34 | +73.1% |
| Profit before tax | 157.93 | (79.60) | — | 25.77 | +513% |
| Profit after tax | 102.92 | (117.62) | — | (17.37) | — |
| Total comprehensive income | 68.63 | (135.69) | — | (0.58) | — |
| Basic EPS | 0.01 | (0.02) | — | (0.00) | — |
- Total income
- Latest 8,671.85; Year ago 3,310.19 (+162%); Prev qtr 5,008.34 (+73.1%)
- Profit after tax
- Latest 102.92; Year ago (117.62); Prev qtr (17.37)
- Period
- September 30, 2026
Also decided at the meeting
- Approved sale/disposal of entire equity stake in wholly owned subsidiary Clinigenome India Private Limited to Micro Genomics India Private Limited; expected completion on or before March 31, 2027.
- Approved resignation of Mr. Hardik Makwana, Company Secretary and Compliance Officer, effective close of business hours on November 16, 2026.
Auditor's review
Conclusion: Unmodified
Notes to the results
- Board approved plan to sell entire stake in subsidiary Clinigenome India Private Limited; its assets and liabilities classified as held for sale under Ind AS 105; no impairment loss recognised.
Results first
- The board considered and approved the Un-audited Standalone & Consolidated Financial Results along with the Limited Review Report of the Statutory Auditor for the quarter and half year ended September 30, 2026.
- On a standalone basis, Revenue from operations for the quarter ended September 30, 2026 was 5,083.08 lakh, compared with 4,478.44 lakh in the quarter ended June 30, 2026.
- Standalone Profit before tax for the quarter was 306.33 lakh and Profit for the period was 257.35 lakh.
- For the half year ended September 30, 2026, standalone Total income was 9,825.05 lakh and Profit for the period was 414.31 lakh.
- The standalone statement shows net cash used in operating activities of 1,009.36 lakh for the half year ended September 30, 2026.
- Amounts are as printed, in INR Lakhs. The auditor's limited review report on the standalone results states that nothing has come to its attention that causes it to believe the statement has not disclosed the required information or contains any material misstatement.
Clinigenome stake sale
- The board considered and approved the Disinvestment/Sale/Disposal of the entire equity stake held in its wholly owned subsidiary Clinigenome India Private Limited.
- Clinigenome India Private Limited is not a material subsidiary; on completion of the sale it will cease to be a wholly owned subsidiary.
- During the last financial year it contributed turnover of 100.47 lakh, being 0.72% of the consolidated turnover, and its net worth was (154.41) lakh as printed.
- The board has identified Micro Genomics India Private Limited as the proposed buyer; the proposed buyer does not belong to the promoter, promoter group or group companies.
- The sale is expected to be completed on or before March 31, 2027, or such other date as may be determined and approved by the board. The consideration will be the amount determined, negotiated and approved by the board.
- In the standalone accounts the investment is classified as Non-current assets held for sale as at September 30, 2026, measured at the lower of carrying amount and fair value less costs to sell, with no impairment loss recognised on this classification for the period ended September 30, 2026.
Company secretary change
- The board considered and approved the Resignation of Mr. Hardik Makwana, Company Secretary and Compliance Officer, from his position with effect from close of business hours on November 16, 2026.
What a retail investor can take away
- This is a quarterly board outcome covering three separate decisions: results, a subsidiary exit and a change in the compliance role.
- The entity being sold is small relative to the group in turnover terms, so the sale is a limited part of the consolidated business by that measure.
- The resignation of the Company Secretary and Compliance Officer is a change in a key compliance position, with the effective date stated in the update.
8,565.82 (Rs. in Lakhs)Revenue from operations, latest quarter
Revenue from operations, quarter4,971.03 (Rs. in Lakhs)
Revenue from operations, year-ago quarter3,263.71 (Rs. in Lakhs)
Profit before tax, latest quarter157.93 (Rs. in Lakhs)
Profit after tax, latest quarter102.92 (Rs. in Lakhs)
Total comprehensive income, latest quarter68.63 (Rs. in Lakhs)
0.72%Clinigenome turnover as share of consolidated turnover
Also from Genpharmasec
Board meeting on 3 November 2026 to approve September quarter results
29 Oct 2026
Subsidiary renamed with FZCO suffix under revised DMCC naming rules
14 Oct 2026
More numbers
- Revenue from operations, standalone, quarter ended Sep 30, 20265,083.08 lakh
- Profit before tax, standalone, quarter ended Sep 30, 2026306.33 lakh
- Profit for the period, standalone, quarter ended Sep 30, 2026257.35 lakh
- Total income, standalone, half year ended Sep 30, 20269,825.05 lakh
- Profit for the period, standalone, half year ended Sep 30, 2026414.31 lakh
- Clinigenome turnover in the last financial year100.47 lakh
- Clinigenome turnover as share of consolidated turnover0.72%
- Clinigenome net worth in the last financial year(154.41) lakh
- Total income, latest quarter8,671.85 (Rs. in Lakhs)
- Total income, year-ago quarter3,310.19 (Rs. in Lakhs)
- Total income, previous quarter5,008.34 (Rs. in Lakhs)
- Total comprehensive income, latest quarter68.63 (Rs. in Lakhs)
- Total comprehensive income, year-ago quarter(135.69) (Rs. in Lakhs)
- Total comprehensive income, previous quarter(0.58) (Rs. in Lakhs)
- Profit after tax, latest quarter102.92 (Rs. in Lakhs)
- Profit after tax, year-ago quarter(117.62) (Rs. in Lakhs)
- Profit after tax, previous quarter(17.37) (Rs. in Lakhs)
- Revenue from operations, latest quarter8,565.82 (Rs. in Lakhs)
- Revenue from operations, year-ago quarter3,263.71 (Rs. in Lakhs)
- Revenue from operations, previous quarter4,971.03 (Rs. in Lakhs)
- Profit before tax, latest quarter157.93 (Rs. in Lakhs)
- Profit before tax, year-ago quarter(79.60) (Rs. in Lakhs)
- Profit before tax, previous quarter25.77 (Rs. in Lakhs)
Source: BSE · 3 Nov 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.